GT Biopharma Partners with University of Minnesota for Phase 1a/1b Trial of GTB-5550 in Solid Tumors

On April 3, 2026, GT Biopharma, Inc. entered into an Investigator Initiated Clinical Trial Agreement with the Regents of the University of Minnesota. Under the agreement, the University will sponsor an Investigational New Drug (IND) application (IND 169118) and conduct a Phase 1a/1b clinical trial evaluating GTB-5550. GTB-5550 is a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE) designed for the treatment of select advanced solid tumors that have failed prior therapy. The Company will bear the budget for the study, which is estimated at approximately $3.8 million over three years. The University's Dr. Nicholas Zorko will serve as the Sponsor-Investigator for the trial. GT Biopharma maintains an exclusive worldwide license to the TriKE technology platform through a separate agreement with the University. The contract includes provisions for intellectual property ownership, publication rights for both parties, and an option for GT Biopharma to acquire exclusive licenses to any new inventions resulting from the study. The agreement can be terminated by either party with 30 days' notice.